E. Ncx, .. Administre, I. Et-ncx-320, .. De, . Au et al., 86 FIGURE 40 : TEMPS, p.88

V. Tableau, de l'aspirine (300 mg/kg en dose unique), du clopidogrel (75 mg/kg/j pendant 5 jours) et le mononitrate d'isosorbide

. En-novembre, Nicox signe un contrat de licence exclusif avec Fera Pharmaceuticals pour le développement et la commercialisation du naproxcinod aux Etats-Unis. Fera pharmaceuticals se concentre sur le traitement des signes et symptômes de l'arthrose. Des travaux supplémentaires devront être requis avant de soumettre à nouveau un dossier de New Drug Application, 2015.

B. 1. Stankevicius, E. Kevelaitis, E. Vainorius, and E. , Role of nitric oxide and other endothelium-derived factors, Medicina, pp.39-43, 2003.

G. , X. Rischmann, P. Arnal, and J. , Nitric oxide pathway and female lower urinary tract. Physiological and pathophysiological role, J Assoc Fr Urol, vol.23, issue.11, pp.926-935, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-01015446

G. , Y. Labarden, and G. , Rapport IST : le monoxyde d'azote. Universite?deUniversite?de Versailles Saint Quentin en Yvelines, 2003.

P. , P. Beckman, J. S. Liaudet, and L. , Nitric oxide and peroxynitrite in health and disease, Physiol Rev, vol.87, issue.1, pp.315-424, 2007.

R. , J. D. Fineman, J. Morin, and F. , Inhaled nitric oxide and persistent pulmonary hypertension of the new born, New Engl J Med, vol.6, pp.336-605, 1997.

S. , R. A. Kuo, and P. C. , Nitric Oxide: physiology et pharmacology, Anesth Analg, vol.81, pp.1052-1059, 1995.

. Air-pays-de-la-la-loire, Les oxydes d'azote, 2006.

W. , G. Morris, and S. M. , Arginine metabolism: nitric oxide and beyond, Biochem J, vol.336, pp.1-17, 1998.

T. , N. Chandra, M. Tuteja, and R. , Nitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology, J Biomed Biotechnol, vol.4, pp.227-237, 2004.

A. , W. K. Cooper, C. E. &knowles, and R. G. , Nitric oxide synthases: structure, function and inhibition, J Biochem, vol.357, pp.593-615, 2001.

F. , U. Sessa, and W. , Nitric oxide synthases: regulation and function

A. , J. Besson-bard, A. Wawer, and I. , Nitric oxide signaling in plants : cross-talk with Ca2+ , protein kinases and reactive oxygen species, Annu Plant Rev, vol.42, pp.147-170, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00425512

F. , A. Koesling, and D. , Regulation of nitric oxide-sensitive guanylyl cyclase

T. and J. Marc, Rôle clinico-biologique du monoxyde d'azote.Thèse de Docteur de l, 2010.

L. , K. A. Pitari, G. M. Kazerounian, and S. , Guanylyl cyclases and signaling by cyclic GMP, Pharmacol Rev, vol.523, pp.375-414, 2000.

A. , H. Ferro, and A. , S-Nitrosothiols: a class of nitric oxide-donor drugs, Clinical sc, pp.98-507, 2000.

E. , D. Z. Sharif, N. A. Dismuke, and W. M. , Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling, Invest Ophthalmol Vis Sci, issue.11, pp.51-5817, 2010.

K. , F. Kassis, M. Coatantiec, and Y. , Hypertension artérielle pulmonaire persistante du nouveau-né et monoxyde d'azote : de la physiologie a la thérapeutique, J Pédiatr Puériculture, vol.10, issue.4, pp.195-199, 1997.

T. , B. Mercier, and J. , Le monoxyde d'azote inhalé : un traitement plus physiologique de l'hypertension artérielle pulmonaire persistante du nouveau-né, Arch Pédiatr, vol.4, pp.988-1003, 1997.

. Embryologie-humaine, Circulation foetale et postnatal. [en ligne] Site disponible sur

D. De, L. Roque, E. Storme, L. Mauriat, and P. , Hypertension pulmonaire de l'enfant et du nouveau-né en réanimation

C. , J. E. Belik, and J. , Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment, J Pediatr, vol.893, pp.226-242, 2013.

V. , R. Rigo, V. Rigo, and J. , Actualités thérapeutiques dans l'hypertension artérielle pulmonaire persistante du nouveau-né, Rev Med Liege, vol.62, pp.5-6, 2007.

. Haute-autorité-de-santé and . Inomax, Commission de la transparence, 2014.

I. Therapeutics and . Inomax®, nitric oxide) for inhalation, 2011.

D. , P. L. Kohlmann, S. T. John, and R. P. , Nitric oxide delivery system, Brevet US, vol.5558083, pp.24-33

P. , M. Dupuis, F. Maincent, and P. , Which future in cardiovascular therapy for nitric oxide and its derivatives?, Ann Pharm Fr, pp.71-84, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01291781

L. and P. Qu, est ce que la schizophre?nischizophre?ni ?Fondation fondamental Réseau de coopération scientifique en santé mentale, 2015.

M. , J. P. Lobão-soares, B. Baker, and G. B. , Sodium nitroprusside, a nitric oxide donor for novel treatment of schizophrenia, may also modulate dopaminergic systems, Schizophr Res, vol.159, pp.2-3, 2014.

H. , J. E. , M. , J. P. Abrao, and J. , Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial, JAMA Psychiatry, vol.7, pp.70-668, 2013.

. Haute-autorité-de-santé and . Isocard, Commission de la transparence, 2012.

. Haute-autorité-de-santé and . Langoran, Commission de la transparence, p.3, 2012.

. Haute-autorité-de-santé and . Risordan, Commission de la transparence, 2012.

. Haute-autorité-de-santé and . Nitronal, Commission de la transparence, 2007.

. Haute-autorité-de-santé and . Corvasal, Commission de la transparence, 2015.

M. , S. Ma, and C. C. , Recent developments in the effects of nitric oxide-donating

M. , S. Impagnatiello, F. Guzzetta, and M. , NCX 6560, a nitric oxidereleasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows antiinflammatory and anti-thrombotic properties, Eur J Pharmacol, vol.570, pp.1-3, 2007.

C. Anatomie and . Physiologie, Anatomie et physiologie de l'oeil, 2015, 2016.

. Société-francaise-du-glaucome and . Glaucome, Site disponible sur :<www.leglaucome.fr>

N. , J. A. Mckee, and M. , Alterations of ocular nitric oxide synthase in human glaucoma, Invest Ophthalmol Vis Sci, vol.36, issue.9, pp.1774-1784, 1995.

N. , J. A. Mckee, and M. , Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye

S. , W. D. Lei, and Y. Boussommier-calleja, eNOS, a pressuredependent regulator of intraocular pressure, Invest Ophthalmol Vis Sci, vol.13, pp.52-9438, 2011.

. Clinicaltrials and . Gov, Étude comparant la sécurité et l'efficacité de BOL-303259-X au latanoprost chez des sujets atteints de glaucome ou d'hypertension oculaire

W. , R. N. Ong, T. Scassellati-sforzolini, and B. , A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study, Br J Ophthalmol, vol.6, pp.99-738, 2015.

W. , R. N. Ong, T. Scassellati-sforzolini, and B. , A prospective randomized, multicenter, single-masked, parallel, dose ranging (voyager) Study to compare the safety and efficacy of BOL-303259-X to latanoporst in subjects with open angle glaucoma or ocular hypertension, Am Glaucoma Soc, vol.23, issue.19

N. , R. Katz, and L. J. , Novel glaucoma drug rivals standard therapy. [en ligne] Site disponible sur <http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/novelglaucoma-drug-rivals-standard-therapy#>

. Clinicaltrials and . Gov, Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension (LUNAR). [en ligne] Site disponible sur <http://clinicaltrials.gov/show, p.1749930

. Clinicaltrials and . Gov, Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension (APOLLO)

. Clinicaltrials and . Gov, A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension (JUPITER). [en ligne] Site disponible sur : <http://clinicaltrials.gov/show, p.1895972

. Association-francaise-contre-les-myopathies, La prise en charge dans la dystrophie musculaire de Duchenne, Orphanet, 2009.

S. Antipolis, Nicox reçoit une opinion positive pour le naproxcinod sur la désignation de médicament orphelin en Europe dans la Dystrophie Musculaire de Duchenne, 2016.

B. , S. Sciorati, C. D-'antona, and G. , Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy, Proc Natl Acad Sci, vol.104, issue.1, pp.264-249, 2007.

C. , E. Cossu, G. Brunelli, and S. , Use of nitrooxyderivative of drug for the treatment of muscular dystropphies

C. , E. Voisin, V. Fossier, and P. , Muscular nitric oxide synthase (muNOS) and utrophin, J Physiol, vol.96, pp.1-2, 2002.
URL : https://hal.archives-ouvertes.fr/hal-00171305

M. , D. Sciorati, C. De-palma, and C. , Naproxcinod, a nitric oxidedonating anti-inflammatory compound, is effective in two mouse models of muscle dystrophy, Neuromuscul Disord, vol.23, pp.9-10, 2013.

N. , K. Uaesoontrachoon, K. Quinn, and J. , Long term treatment with naproxcinod significantly improves skeletal and cardiac function in mdx mouse model of dystrophy, Neuromuscul Disord, vol.201323, pp.9-10799

G. , K. Ergenekon, E. Erbas, and D. , The serum nitric oxide levels in patients with Duchenne muscular dystrophy, Brain Dev, vol.223, pp.181-183, 2000.

S. Antipolis, Résultats précliniques pour le naproxcinod sur des modèles de dystrophie musculaire présentés à la MDA Scientific Conference, 2016.